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The asialoglycoprotein receptor (ASGP-R) is a glycoprotein
present in large amount only on hepatocytes where it is expressed
on the sinusoidal and lateral plasma membrane (Morell et al, 1968;
Geffen and Spiess, 1992). ASGP-R binds and internalizes a broad
range of molecules exposing galactose or N-acetyl-galactosamine
residues. Following internalization the fate of ligand is lysosomal
degradation (Morell et al, 1968; Geffen and Spiess, 1992).
Taking advantage of this receptor a chemotherapeutic approach
has been developed to reduce the extrahepatic side-effects of
nucleoside analogues (NAs) used in chronic viral hepatitis (Fiume
et al, 1979, 1997; Torriani et al, 1996). These drugs are coupled to
galactosyl-terminating peptides. The conjugates selectively enter
hepatocytes, where the lysosomal enzymes split the bond between
the carrier and the drug, which becomes concentrated in liver
cells. A similar strategy was suggested in order to increase the
chemotherapeutic index of drugs inhibiting DNA synthesis in the
treatment of human hepatocellular carcinoma (HCC) (Schneider
et al, 1984; O’Hare et al, 1989; Di Stefano et al, 1998). This
approach obviously requires the presence of the receptor in the
neoplastic tissue and maintenance of its expression on DNA
synthesizing cells.
Few and conflicting data are available on the distribution of
ASGP-R in human neoplastic hepatocytes. In a study in which the
receptor was measured by a biochemical procedure, it was not
found in HCC samples (Sawamura et al, 1984), whereas in an
immunohistochemical investigation carried out on ten cases of
HCC the presence of the receptor was demonstrated in the more
differentiated forms (Hyodo et al, 1993). In the present study we
have first assessed the frequency of ASGP-R expression in a large
number of human HCCs. For this purpose, needle biopsy samples
of sixty consecutive HCCs were analysed. Visualization of the
receptor was obtained using an anti-ASGP-R monoclonal antibody
applied after antigen retrieval procedure to routinely formalin-
fixed, paraffin-embedded liver samples. Since we found that the
ASGP-R was present in 33 HCCs we also investigated whether the
ASGP-R was maintained on the plasma membrane of DNA
synthesizing cancer cells. For this purpose we incubated HCC
tissue samples with bromodeoxyuridine (BrdU). The presence of
ASGP-R on DNA-synthesizing cancer cells was immunohisto-
chemically assessed using anti-BrdU and anti-ASGP-R antibodies
on the same tissue section.
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SummaryThe expression of the asialoglycoprotein receptor (ASGP-R) on human hepatocellular carcinoma (HCC) cells might be exploited to
reduce the extrahepatic toxicity of DNA synthesis inhibitors by their conjugation with galactosyl-terminating peptides. In the present study we
first assessed the frequency of ASGP-R expression in 60 HCCs. Secondly, we investigated whether the receptor was maintained on the
plasma membranes of DNA synthesizing cancer cells. Needle biopsies of HCC were evaluated. Diagnosis and grading of HCC were
performed on routine haematoxylin and eosin-stained sections according to Edmondson and Steiner (1953). Thirty-five tumours were grade I
and II and were classified as well differentiated, while 25 tumours were grade III and IV and were classified as poorly differentiated. Sections
from formalin-fixed, paraffin-embedded samples were incubated, after antigen retrieval, with an anti-ASGP-R monoclonal antibody revealed
by secondary biotinylated antibody and streptavidin–biotin–peroxidase–diaminobenzidine reaction. A clear immunolabelling of plasma
membranes of HCC cells was observed in 28 out of 35 (80%) well differentiated (grade I and II) and in five out of 25 (20%) poorly differentiated
(grade III and IV) HCCs. The presence of the ASGP-R on the surface of DNA synthesizing cancer cells was also investigated after in vitro
bromodeoxyuridine (BrdU) labelling of HCC samples by immunohistochemical visualization of both the ASGP-R and incorporated BrdU on
the same section. The results obtained clearly demonstrated that DNA synthesizing cancer cells expressed the ASGP-R on their surface. The
presence of ASGP-R on cell plasma membrane in the majority of differentiated HCCs and its maintenance on proliferating cells encourages
studies in order to restrict the action of the inhibitors of DNA synthesis of HCC cells by their conjugation with galactosyl-terminating carriers
internalized through this receptor.©1999 Cancer Research Campaign
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MATERIALS AND METHODS
Specimens
A surgically resected liver tissue sample adjacent to metastasis
of colonic adenocarcinoma was fixed in 10% neutral-buffered
formalin and routinely paraffin-embedded.
Needle biopsies from 60 consecutive cases of HCCs from the
archives of the Department of Morphological Sciences and Legal
Medicine, Section of Anatomic Pathology, of Modena University
were evaluated. This series included only primary HCCs. Samples
had been fixed in 10% neutral-buffered formalin and routinely
paraffin-embedded. Diagnosis and grading of HCC were
performed on routine haematoxylin and eosin (H&E)-stained
sections according to Edmondson and Steiner (1953).
Surgically resected liver samples from three patients with
primary HCC were processed for in vitro BrdU labelling as
described by Trerè et al (1991). Briefly, immediately after surgical
resection the histological sample was divided into small pieces
with a maximum diameter of 0.5–1.0 mm which were then
immersed in 5 ml of RPMI-1640 containing non-essential amino
acids (Seromed, Biochrom KG), 100 U ml–1 penicillin, 100 mgm l –1
streptomycin and 10% fetal calf serum (FCS) supplemented with
160 mM BrdU (Sigma Co., USA), and incubated for 4 h at 37°C in
a 5% carbon dioxide–air incubator. Tissues were then rapidly
rinsed with three changes of cold phosphate-buffered saline (PBS)
(0.01 M, pH 7.5) and fixed in 70% ethanol for 48 h at 4°C. Finally,
tissues were routinely processed and embedded in paraffin.
Patients
Forty-four men and 16 women were studied, with a mean age of
63 ± 12 years. Serum markers for hepatitis B virus (HBV), anti-
HCV antibodies and a-fetoprotein (AFP) were assessed by
commercial kits. Fifty-four patients had cirrhosis. This was related
to alcohol abuse alone in five, alcohol abuse combined with
chronic hepatitis C in two, HBV infection in 14 and HCV infection
in 31. No risk factors were recognized in two cirrhotic patients.
The remaining six patients included four with chronic hepatitis B,
one with chronic hepatitis C and one with histologically normal
liver. Tumour size was evaluated at the time of HCC diagnosis by
ultrasound examination.
ASGP-R immunolabelling
From each paraffin block, 3- to 4-mm-thick sections were cut,
cleared in xylene and rehydrated. Slides were then removed from
water to plastic slide holders, fully immersed in 10 mM sodium
citrate buffer (pH 6.0) and heated for 20 min at 120°C in a
commercially available pressure cooker. After cooling to room
temperature in the sodium citrate buffer, slides were treated with
a solution of 0.3% hydrogen peroxide (H2O2) in methanol for
30 min at room temperature to abolish endogenous peroxidase
activity. Sections were then incubated for 10 min in a moist
chamber with non-immune rabbit serum diluted to 5% in PBS
pH 7.2–7.4 to reduce non-specific background staining. Sections
were then incubated overnight at 4°C with the primary antibody
(anti-ASGP-R monoclonal antibody, purchased from Daiichi Pure
Chemicals Co. Ltd, Tokyo, Japan) diluted 1:200. This antibody
was produced by Kohgo et al (1993) by immunizing Balb-c mice
with the ASGP-R purified from human liver. Sections were subse-
quently incubated with rabbit anti-mouse Ig biotinylated antibody
(Dako, Glostrup, Denmark) diluted 1:600 in PBS with 5% normal
human AB serum for 30 min, and then in a streptavidin–
biotin–peroxidase preformed complex (Dako, Glostrup, Denmark)
for 30 min. The immunologic reaction was developed using 3,3¢-
diaminobenzidine-tetra-hydro-chloride-H2O2 solution, dehydrated
and mounted with Canada balsam (Merck, Darmstadt, Germany).
A negative control was performed by omitting the anti-ASGP-R
monoclonal antibody.
Double immunolabelling for ASGP-R and BrdU
From the paraffin-embedded small tissue samples, which had been
incubated in vitro with BrdU, 3- to 4-mm-thick sections were cut,
cleared in xylene and rehydrated, through graded ethanol to
distilled water. Slides were placed in plastic slide holders and
heated for 20 min at 120°C as previously described. After cooling
in the sodium citrate buffer, slides were treated with a solution of
0.3% H2O2 in methanol for 30 min to abolish endogenous peroxi-
dase activity, and treated with 4 N hydrochloric acid at room
temperature for 20 min. Sections were then incubated in a moist
chamber with non-immune rabbit serum diluted to 5% in PBS
pH 7.2–7.4 for 10 min to reduce non-specific background staining,
and then incubated with an anti-BrdU monoclonal antibody
diluted 1:500 (Becton Dickinson, USA) for 1 h at room tempera-
ture. After three washes in PBS (10 min each), sections were
incubated overnight at 4°C with the anti-ASGP-R monoclonal
antibody diluted 1:200. The immunoreaction was then developed
as previously described. For each experiment, three negative
controls were performed by omitting the anti-ASGP-R mono-
clonal antibody (control I), the anti-BrdU monoclonal antibody
(control II) and both monoclonal antibodies (control III) respec-
tively.
Statistical analysis
Differences between groups were evaluated by the ANOVA test.
A P-value lesser than 0.05 was considered to be significant.
RESULTS
Clinical and histopathological characteristics HCCs
AFP levels ranged from 1.6 to 1690 ng ml–1, with a mean value of
204.4 ± 382.3 ng ml–1. The maximum diameter of HCCs ranged
from 1.5 to 12 cm, with a mean value of 4.34 ± 2.60 cm.
Histological grade of HCCs was assessed according to
Edmondson and Steiner (1953). Thirty-five tumours were grade I
and II and were classified as well differentiated. Twenty-five
tumours were grade III and IV and were classified as poorly differ-
entiated. Two out of the three surgically resected HCCs processed
for in vitro BrdU labelling were grade II and one was grade III.
Expression of the ASGP-R on human normal
hepatocytes
Immunohistochemical staining of ASGP-R in formalin-fixed,
paraffin-embedded human liver tissue adjacent to metastasis of a
colonic adenocarcinoma revealed oxidized diaminobenzidine
deposits mainly located on the sinusoidal margins of the liver406 D Trerè et al
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cords. Occasionally, the immunoreaction was also visible on the
lateral plasma membrane, where the quantity of reaction product
was always lower. The staining reaction appeared to be uniformly
distributed throughout the three acinal zones. In normal liver spec-
imens no immunolabelling on the cytoplasm of the hepatocytes
was observed (Figure 1). If the anti-ASGP-R monoclonal antibody
was omitted from the immunostaining procedure, plasma
membranes were not labelled.
Expression of the ASGP-R on human HCCs
HCCs were judged as positive for ASGP-R expression when all
the cancer cells exhibited clear-cut staining of the plasma
membranes (Figure 2). Immunostaining of the cancer cell plasma
membranes was clearly observed in 28 out of the 35 (80%) well
differentiated and in five out of the 25 (20%) poorly differentiated
HCCs. The intensity of the staining reaction was not to the same
degree in the 33 positive HCCs. A loss of the polarized location of
ASGP-R, typical of the normal hepatocytes (Geffen and Spiess,
1992), appeared to occur in the positive HCCs. Cancer cells were
delimited by a uniformly stained plasma membrane (Figure 3). In
seven out of the 35 well differentiated, and in 20 out of the 25
poorly differentiated HCCs no ASGP-R immunostaining was
detected. Only a very light, unspecific staining of all cellular
components was observed. In some cases a granular immuno-
labelling was detected throughout the cytoplasm of cancer cells,
regardless of the presence of plasma membrane immunopositivity.
In all biopsies showing non-tumour areas adjacent to HCC,
normal hepatocytes were found to be positive for ASGP-R
immunostaining, independently of ASGP-R expression of cancer
cells. No significant differences were found in the AFP levels
between ASGP-R positive and negative patients, and no correla-
tion was demonstrated between ASGP-R expression and aetiology.
The maximum diameters of HCCs which did not present the
ASGP-R were larger than those of HCCs exhibiting the ASGPR
(5.10 ± 2.49 and 3.63 ± 2.54 cm respectively; F = 4.635; P =
0.036). However, the correlation between ASGP-R expression and
tumour size was due to the fact that well differentiated HCCs
were significantly greater than poorly differentiated HCCs (with
maximum diameters of 5.15 ± 3.01 and 3.69 ± 2.04 cm respec-
tively F = 4.488; P = 0.039).
Expression of the ASGP-R on DNA synthesizing cancer
cells
When ASGP-R was immunohistochemically assessed in the three
surgically resected HCCs processed for in vitro BrdU labelling, it
was found to be expressed on the plasma membranes of the two
grade II tumours, while the grade III tumour did not show any
Figure 1–3 Sections treated with anti ASGP-R monoclonal antibody
revealed by peroxidase–diaminobenzidine reaction.
Figure 1 Normal liver. The staining reaction is exclusively confined to the
luminal and lateral plasma membranes of the hepatocytes. No other cellular
structures are stained (´ 1200)
Figure 2 Well differentiated HCCs. All HCC cells exhibit a selective
immunostaining of plasma membranes (A, ´ 150; B and C, ´ 350)
B
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immunostaining. A similar ASGP-R immunostaining was
observed in the corresponding tumour samples routinely formalin-
fixed and paraffin-embedded. The BrdU labelling indices of these
HCCs, expressed as per cent labelled nuclei over at least 2000
cells counted directly at the microscope, were 7.2 and 8.1 in the
two Grade II tumours respectively, and 6.6 in the grade III tumour.
To demonstrate the contemporary presence of BrdU-positive
nuclei and ASGP-R expression in the same cell, visualization of
both BrdU and ASGP-R was carried out on the same tissue section
from the two HCCs expressing the ASGP-R out of the three HCCs
pre-treated by in vitro incubation with BrdU. All BrdU-positive
cells also exhibited an evident ASGP-R expression. In Figure 4
cancer cells in which the plasma membranes are clearly stained by
anti-ASGP-R monoclonal antibody are shown: in two cells clear
immunopositivity for BrdU is also observed in the nuclei.
DISCUSSION
The present study, carried out on 60 consecutive human HCCs,
demonstrated that the ASGP-R, as revealed using a specific
monoclonal antibody, was present in 28 out of 35 well differen-
tiated (grade I and II) and in five out of 25 poorly differentiated
(grade III and IV) HCCs. The ASGP-R was immunohistochemi-
cally visualized in routinely formalin-fixed, paraffin-embedded
tissues samples after the antigen retrieval procedure. We have also
observed that in ASGP-R-positive HCCs the immunostaining
reaction decorated all the cells composing the neoplastic tissue.
This finding suggested that also the proliferating cells of the
cancer lesions should express the ASGP-R on their surface. To get
a direct evidence that dividing human hepatocarcinoma cells
express the ASGP-R we in vitro labelled HCC samples with BrdU
and immunocytochemically visualized both the ASGP-R and
incorporated BrdU on the same tissue section. The results obtained
clearly demonstrated that DNA synthesizing cells maintained the
ASGP-R on their plasma membranes.
Our data are consistent with and extended the observations of
Hyodo et al (1993) who examined ten cases of HCCs character-
ized by various differentiation degree and observed that ASGP-R
was expressed in four of the six differentiated forms. However, no
evidence was obtained by these authors that the receptor was
maintained on the proliferating neoplastic cells.
The presence of ASGP-R on cell plasma membrane in the
majority of differentiated HCCs and its expression on proliferating
cells might be exploited to improve the chemotherapy of these
tumours by conjugation of inhibitors of DNA synthesis with
galactosyl-terminating carriers. In patients with HCC who are
not eligible for surgical treatment or liver transplantation,
chemotherapy either by systemic injection or transcatheter arterial
embolization with anti-tumour agents is used (Bruix, 1997).
However, systemic chemotherapy is characterized by a very low
response rate with extrahepatic tissue toxicity (Bruix, 1997) and
arterial chemo-embolization, even if it increases the local concen-
tration of drugs and reduces systemic side-effects, is somewhat
traumatic, responsible for the painful embolization syndrome and
may favour pulmonary metastasis (Boix et al, 1996). All these
drawbacks might be avoided or reduced by a chemotherapeutic
approach based on the conjugation of anti-proliferating drugs
specifically inhibiting DNA synthesis with carriers which bind to
the ASGP-R. This treatment should kill proliferating hepatocarci-
noma cells without affecting normal resting hepatocytes and the
proliferating cells of other tissues which do not possess the
ASGP-R. Obviously, the prerequisite for this chemotherapeutical
approach is the immunocytochemical detection of the ASGP-R in
the neoplastic specimens obtained by needle biopsy. Only for these
tumours, the treatment with a conjugated drug could be advan-
tageous.
The presence of the receptor on the surface of proliferating
cancer cells does not assure that the conjugated drug after the
ASGP-R binding is internalized and released from the carrier by
lysosomal enzymes as in normal resting hepatocytes. However, in
recent experiments evidence was obtained that this process can
also occur in neoplastic hepatocytes. Using Hep G2 cells, a human
HCC cell line expressing the ASGP-R (Schwartz et al, 1981), it
was found that 5-fluoro-2¢-deoxyuridine conjugated with
lactosaminated poly-L-lysine inhibited cell proliferation after
intracellular penetration through the receptor (Di Stefano et al,
1998). This result, together with the present observations, suggest
conjugation with galactosyl-terminating carriers as a possible way
to restrict the pharmacological action of DNA synthesis inhibitors
to HCC cells and prevent their side-effects on extrahepatic
tissues.
Figure 3 Same sample as in Figure 2A shown at higher magnification
(´ 1200). The plasma membranes of HCC cells are uniformly stained by
the immunolabelling
Figure 4 Well differentiated HCC. The sample was labelled in vitro with
BrdU. The section was immunostained for both BrdU and ASGP-R. Two
cancer cell nuclei are stained (arrowheads); the plasma membrane of these
cells is stained as well as that of the other cancer cells (´ 1200)408 D Trerè et al
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